NovoCodex Pharmaceuticals

NovoCodex is a China-based biopharmaceutical company focused on the research, development, and manufacture of biological products, with particular strength in antibody-drug conjugates. The company is a controlling subsidiary of Zhejiang Medicine and was founded in 2017 in Shaoxing, Zhejiang. Its lead pipeline centers on HER2- and CD70-targeted ADCs, including ARX788 for HER2-positive breast and gastric cancers and ARX305 for CD70-positive tumors. NovoCodex highlights a site-specific conjugation platform based on synthetic amino acid insertion, which it uses to build precision ADCs and other protein therapeutics. The company also reports in-house capabilities spanning genetic engineering, cell culture, toxin synthesis, ADC conjugation, formulation and filling, and preclinical and clinical development.